{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:05:11Z","timestamp":1789707911218,"version":"4.0.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Choroidal osteoma is a rare benign osseous tumor that most commonly occurs in young women, typically located in the choroid near the optic disc or in the macular region. Secondary choroidal neovascularization (CNV) or subretinal fluid (SRF) is the main causes of visual impairment in affected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>This article reports a 36-year-old woman who presented with decreased vision in her right eye. Multimodal imaging confirmed a choroidal osteoma in the right eye complicated by SRF in the macular area. After intravitreal injections of ranibizumab, SRF decreased substantially. Approximately 40 weeks later, the patient reported recurrent visual decline, and macular SRF recurs. After switching to intravitreal injection of faricimab (6\u2005mg\/0.05\u2005mL), the SRF resolved completely, macular complete SRF resolution with restoration of the foveal contour, and visual acuity remained stable throughout subsequent follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that anti-VEGF therapy may be an option for SRF secondary to choroidal osteoma. In recurrent cases without definite CNV, faricimab may facilitate SRF resolution, though the proposed Ang-2-mediated vascular-stabilizing effect requires further validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1973913","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:30:33Z","timestamp":1789705833000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Faricimab in the treatment of subretinal fluid secondary to choroidal osteoma without definite evidence of CNV"],"prefix":"10.3389","volume":"13","author":[{"given":"Ruixue","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Second Clinical College of North Sichuan Medical College, Nanchong Central Hospital","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yang","sequence":"additional","affiliation":[{"name":"North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"Department of Ophthalmology, The Second Clinical College of North Sichuan Medical College, Nanchong Central Hospital","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-2008-1045680","article-title":"Bilaterale chorioidale osteome","volume":"203","author":"Rohrschneider","year":"1993","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"B2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/archopht.1978.03910050204002","article-title":"Choroidal osteoma","volume":"96","author":"Gass","year":"1978","journal-title":"Arch Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1097\/IAE.0000000000000187","article-title":"Outcomes of anti\u2013vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma","volume":"34","author":"Khan","year":"2014","journal-title":"Retina"},{"key":"B4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/eye.2016.50","article-title":"Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma","volume":"30","author":"Papastefanou","year":"2016","journal-title":"Eye"},{"key":"B5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0974-620X.169908","article-title":"Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: long-term results","volume":"8","author":"Lekha","year":"2015","journal-title":"Oman J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00417-021-05487-4","article-title":"Complications, treatments, and visual prognosis of choroidal osteomas","volume":"260","author":"Seong","year":"2022","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/IAE.0b013e3181c720ca","article-title":"Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma","volume":"30","author":"Song","year":"2010","journal-title":"Retina"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/ijms24021064","article-title":"Choroidal neovascular membranes in retinal and choroidal tumors: origins, mechanisms, and effects","volume":"24","author":"Di Staso","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e234357","DOI":"10.1136\/bcr-2020-234357","article-title":"Choroidal osteoma: the varied response of subretinal fluid to anti-VEGF agents","volume":"13","author":"Narang","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier Heier","year":"2022","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA And LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.survophthal.2023.06.002","article-title":"Clinical features and therapeutic management of choroidal osteoma: a systematic review","volume":"68","author":"Zhang","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ajo.2022.08.007","article-title":"Predicting visual outcomes in choroidal osteoma treated with anti-vascular endothelial growth factor","volume":"244","author":"Kang","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00347-023-01912-7","article-title":"[Long-term outcome of macular neovascularization secondary to choroidal osteoma with and without intravitreal anti-VEGF(vascular endothelial growth factor)- treatment]","volume":"120","author":"D\u00fctsch","year":"2023","journal-title":"Die Ophthalmologie"},{"key":"B16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0974-620X.169908","article-title":"Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: long-term results","volume":"8","author":"Lekha","year":"2015","journal-title":"Oman J Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4103\/joco.joco_74_24","article-title":"Antivascular endothelial growth factorsfor the management of choroidal neovascularization associated with choroidal osteoma: a case study-based review","volume":"36","author":"Fekri","year":"2024","journal-title":"J Curr Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","article-title":"Anatomic outcomes with faricimab vs aflibercept in the head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration","volume":"132","author":"Cheung","year":"2025","journal-title":"Ophthalmology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s40123-025-01181-4","article-title":"Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis","volume":"14","author":"Khodor","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3000605261445216","DOI":"10.1177\/03000605261445216","article-title":"Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: a case report","volume":"54","author":"Al Adel","year":"2026","journal-title":"J Int Med Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1973913\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:31:02Z","timestamp":1789705862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1973913\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1973913"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1973913","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1973913"}}